Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab in R/R DLBCL
NCT07269639Phase 2Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golcadomide, poseltinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
golcadomideposeltinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07269639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269639.